Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?
Despite a huge effort by the scientific community to determine the animal reservoir of SARS-CoV-2, which led to the identification of several SARS-CoV-2-related viruses both in bats and in pangolins, the origin of SARS-CoV-2 is still not clear. Recently, Temmam et al. reported the discovery of bat c...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2022-12-01
|
Series: | Journal of Enzyme Inhibition and Medicinal Chemistry |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/14756366.2022.2062336 |
_version_ | 1818272405800353792 |
---|---|
author | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro |
author_facet | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro |
author_sort | Matteo Pavan |
collection | DOAJ |
description | Despite a huge effort by the scientific community to determine the animal reservoir of SARS-CoV-2, which led to the identification of several SARS-CoV-2-related viruses both in bats and in pangolins, the origin of SARS-CoV-2 is still not clear. Recently, Temmam et al. reported the discovery of bat coronaviruses with a high degree of genome similarity with SARS-CoV-2, especially concerning the RBDs of the S protein, which mediates the capability of such viruses to enter and therefore infect human cells through a hACE2-dependent pathway. These viruses, especially the one named BANAL-236, showed a higher affinity for the hACE2 compared to the original strain of SARS-CoV-2. In the present work, we analyse the similarities and differences between the 3CL protease (main protease, Mpro) of these newly reported viruses and SARS-CoV-2, discussing their relevance relative to the efficacy of existing therapeutic approaches against COVID-19, particularly concerning the recently approved orally available Paxlovid, and the development of future ones. |
first_indexed | 2024-12-12T21:41:33Z |
format | Article |
id | doaj.art-d44bc14e26c24861905474b8507c7daa |
institution | Directory Open Access Journal |
issn | 1475-6366 1475-6374 |
language | English |
last_indexed | 2024-12-12T21:41:33Z |
publishDate | 2022-12-01 |
publisher | Taylor & Francis Group |
record_format | Article |
series | Journal of Enzyme Inhibition and Medicinal Chemistry |
spelling | doaj.art-d44bc14e26c24861905474b8507c7daa2022-12-22T00:11:02ZengTaylor & Francis GroupJournal of Enzyme Inhibition and Medicinal Chemistry1475-63661475-63742022-12-013711077108210.1080/14756366.2022.2062336Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)?Matteo Pavan0Davide Bassani1Mattia Sturlese2Stefano Moro3Molecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences University of Padova, Padova, ItalyMolecular Modeling Section (MMS), Department of Pharmaceutical and Pharmacological Sciences University of Padova, Padova, ItalyDespite a huge effort by the scientific community to determine the animal reservoir of SARS-CoV-2, which led to the identification of several SARS-CoV-2-related viruses both in bats and in pangolins, the origin of SARS-CoV-2 is still not clear. Recently, Temmam et al. reported the discovery of bat coronaviruses with a high degree of genome similarity with SARS-CoV-2, especially concerning the RBDs of the S protein, which mediates the capability of such viruses to enter and therefore infect human cells through a hACE2-dependent pathway. These viruses, especially the one named BANAL-236, showed a higher affinity for the hACE2 compared to the original strain of SARS-CoV-2. In the present work, we analyse the similarities and differences between the 3CL protease (main protease, Mpro) of these newly reported viruses and SARS-CoV-2, discussing their relevance relative to the efficacy of existing therapeutic approaches against COVID-19, particularly concerning the recently approved orally available Paxlovid, and the development of future ones.https://www.tandfonline.com/doi/10.1080/14756366.2022.2062336SARS-CoV-2bat coronavirussarbecovirusBANALLaosMPro |
spellingShingle | Matteo Pavan Davide Bassani Mattia Sturlese Stefano Moro Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? Journal of Enzyme Inhibition and Medicinal Chemistry SARS-CoV-2 bat coronavirus sarbecovirus BANAL Laos MPro |
title | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? |
title_full | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? |
title_fullStr | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? |
title_full_unstemmed | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? |
title_short | Bat coronaviruses related to SARS-CoV-2: what about their 3CL proteases (MPro)? |
title_sort | bat coronaviruses related to sars cov 2 what about their 3cl proteases mpro |
topic | SARS-CoV-2 bat coronavirus sarbecovirus BANAL Laos MPro |
url | https://www.tandfonline.com/doi/10.1080/14756366.2022.2062336 |
work_keys_str_mv | AT matteopavan batcoronavirusesrelatedtosarscov2whatabouttheir3clproteasesmpro AT davidebassani batcoronavirusesrelatedtosarscov2whatabouttheir3clproteasesmpro AT mattiasturlese batcoronavirusesrelatedtosarscov2whatabouttheir3clproteasesmpro AT stefanomoro batcoronavirusesrelatedtosarscov2whatabouttheir3clproteasesmpro |